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Abstract
The increased burden of cardiovascular disease in patients with
rheumatoid arthritis and systemic lupus erythematosus has recently
become the focus of intense investigation. Pro-atherogenic risk
factors and dysregulated inflammation are the main culprits,
leading to enhanced atherosclerosis in subgroups of patients with
inflammatory diseases. Common molecular pathways shared by
atherosclerosis and inflammatory disease may be involved. In this
review we map the key determinants of the increased incidence of
cardiovascular disease in patients with inflammatory diseases at
each step of the atherogenesis.
Introduction
Research during the past 20 years has driven a major shift in
how atherosclerosis is conceptualized. Initially branded as a
passive accumulation of lipids in the vessel wall, athero-
sclerosis is now recognised as an ‘inflammatory disease’ [1].
Striking similarities can be identified between atherosclerosis
and prototypical inflammatory diseases (Figure 1). In parallel,
there is growing evidence that cardiovascular disease (CVD)
is the leading cause of mortality in patients with chronic
inflammatory diseases [2], including rheumatoid arthritis (RA),
systemic lupus erythematosus (SLE), Sjögren’s disease and
systemic sclerosis.
This review first summarizes the impact of CVD on the lives of
patients with inflammatory diseases. Second, we map the key
molecular determinants of the increased prevalence of CVD
in patients with inflammatory diseases at each step of the
progression of atherosclerosis (initiation, progression and
thrombotic complications). We focus on RA and SLE, for
which more evidence is currently available.
The clinical impact of atherosclerosis in
inflammatory diseases
Atherosclerosis and rheumatoid arthritis
Cardiovascular manifestations such as pericarditis, myo-
carditis and atrioventricular block are classic complications of
RA and SLE. However, most of the cardiovascular mortality in
RA patients is not due to these manifestations but rather to
ischaemic heart disease secondary to coronary athero-
sclerosis [3]. In the Nurses’ Health Study [4], patients with
RA had more than twofold greater risk for myocardial
infarction (MI) compared with patients without RA. Worry-
ingly, RA patients are almost six times more likely to have had
an undiagnosed MI and twice as likely to experience sudden
death [5]. RA patients are also far less likely to report fore-
warning symptoms, such as angina [5,6], potentially hamper-
ing early detection of atherosclerotic disease.
In support of these observations, RA patients have an
increased prevalence of subclinical atherosclerosis, with a
greater incidence of carotid artery plaque and increased
carotid intima/media thickness (IMT) [7,8] as well as multi-
vessel coronary artery disease compared with control
individuals [9].
Systemic lupus erythematosus and cardiovascular
disease
Three decades ago, Urowitz and coworkers [10] recognized
that CVD and MI were major causes of mortality in patients
with SLE. In fact, patients with SLE are five or six times more
likely to have a significant coronary event compared with the
general population. Remarkably, women with SLE between
the ages of 35 and 44 years have a 50-fold increased risk for
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MI compared with age-matched and sex-matched control
individuals [11]. In a Canadian cohort of SLE patients, the
relative risk for MI was 10.1, that for death due to CHD was
17, and that for stroke was 7.9 [12]. SLE patients have
increased subclinical atherosclerosis compared with the
general population, with a greater prevalence of carotid
plaques and increased IMT [13,14]. Myocardial single photon
emission computed tomography scanning has revealed
coronary artery disease in 40% of patients with SLE [15,16],
although coronary artery calcification is more prevalent in
lupus without underlying CVD [17].
Risk factors for cardiovascular events in
patients with rheumatoid arthritis and
systemic lupus erythematosus
Clustering of traditional atherogenic risk factors
RA and SLE patients have an overall increased frequency of
traditional cardiovascular risk factors [3,10,18,19]. Smoking is
associated with subclinical atherosclerosis in patients with
RA [20]. Hypertension is also an important risk factor for
CVD in RA and SLE [21,22].
A particular type of dyslipidaemia is present in patients with
RA. This is characterized by low high-density lipoprotein
(HDL), raised triglycerides and low levels of low-density lipo-
protein (LDL) [23]. Interestingly, such a lipid profile is
detectable in those individuals who go on to develop RA at
least 10 years before the onset of symptoms [24]. Dyslipo-
proteinaemia in SLE is slightly different from that in RA,
characterized by elevated levels of very-low-density
lipoprotein cholesterol and triglycerides, high or unchanged
LDL, low levels of HDL and disturbance in chylomicron
metabolism. Hence, low HDL levels are a common trait in RA
and SLE. Low HDL in the general population exhibits a strong
inverse correlation with CVD events, even in the presence of
low LDL or statin therapy. Changes in lipoprotein functions
have also been described. For instance, LDL from RA
patients has an increased capacity to bind proteoglycans,
which is considered an important early step in atherogenesis
[25]. High levels of the pro-atherogenic lipid particle lipo-
protein-a have been detected in both diseases, as well as
elevated levels of circulating oxidized LDL (oxLDL) [26].
Paraoxonase, an enzyme that binds to HDL and prevents oxi-
dation of LDL, was shown to have reduced activity in patients
with SLE and primary antiphospholipid syndrome [27].
Patients with RA and SLE have a higher prevalence of
metabolic syndrome [28], which includes obesity, dyslipid-
aemia, hypertension and insulin resistance. Additionally,
patients with RA and SLE are less physically active than
individuals without the disease, which may also contribute to
accelerated atherosclerosis.
Traditional therapies and cardiovascular risk
The effect of chronic use of drugs commonly employed to
treat RA and SLE in promoting or suppressing atherogenesis
Figure 1
Similarities between the atherosclerotic plaque and rheumatoid arthritis joint. The (a) atherosclerotic plaque has many features in common with (b)
rheumatoid arthritic synovium. First, in both diseases, blood-borne mononuclear cells are recruited to sites that are devoid of any significant
inflammation in physiological conditions. Second, upregulation of cytokines and matrix-degrading enzymes is central to the pathogenesis of both
diseases. Third, both in rheumatoid arthritis and atherosclerosis, immune cells do not target resident cells in the same way that diabetogenic T cells
directly destroy pancreatic islets. Instead, immune cells begin complex interactions with the resident cell types, which proliferate, change their
properties and phenotype, and contribute to the inflammatory process and tissue destruction.is extensively reviewed elsewhere [23,29]. Such drugs can
affect the progression of atherosclerosis either by acting on
the inflammatory process or by altering cardiovascular risk
factors. Corticosteroids, for instance, promote insulin resis-
tance, weight gain, fluid retention and hypertension. None-
theless, within the context of inflammatory diseases their net
effect is likely to be complex because of their beneficial
effects on the ongoing inflammation. In the COBRA
(Combination Therapy in Early Rheumatoid Arthritis) study
[30], high-dose steroids used in conjunction with other
disease-modifying antirheumatic drugs improved the total
cholesterol to HDL ratio, with a linear association with the
Disease Activity Score. However, in a different study [31]
glucocorticoid exposure was associated with carotid plaque
and arterial incompressibility.
The effect of methotrexate is similarly complex. Methotrexate
use causes elevation in serum homocysteine levels by folate
depletion. This effect could promote atherogenesis as
because hyperhomocysteinaemia is an independent risk
factor associated with CVD in the general population as well
as in patients with SLE [32]. However, in a prospective study
involving 1,240 patients with RA [33], therapy with metho-
trexate was associated with improved survival by reducing
CVD mortality by 70%. Folate supplementation is a plausible
approach to counteract hyperhomocysteinaemia [34] and is
currently a matter of debate. It is worth noting that in a trial of
5,442 women conducted over 7 years [35], daily supplemen-
tation with a combination of folate and vitamins B6 and B12
was able to reduce hyperhomocysteinaemia, but it was
unable to abolish CVD risk.
Nonsteroidal anti-inflammatory drugs are among the most
commonly used anti-inflammatory interventions. This group of
drugs has a much broader range of actions than simply
inhibition of inflammation, including their effect on prosta-
glandin metabolism, in which atheroprotective mediators (for
example, prostacyclin) are also inhibited. In a recent meta-
analysis [36] selective cyclo-oxygenase-2 inhibitors and high-
dose regimens of ibuprofen and diclofenac were found to be
associated with a moderate increase in the risk for adverse
cardiovascular events.
Inflammatory burden and atherosclerosis
Both SLE and RA patients exhibit an increased prevalence of
pro-atherogenic risk factors, which may very well contribute
to the burden of CVD events and atherosclerotic disease.
However, there is growing evidence that this is only one side
of the story.
In a number of studies, even after correction for classical risk
factors for CVD, both RA and SLE remain independently
associated with clinical and subclinical atherosclerosis [9,18]
(Tables 1 and 2). In a cohort of 296 SLE patients followed for
a mean of 8.6 years, CVD events were substantially higher
than would be predicted on the basis of traditional factors
alone, using the Framingham risk stratification method [12]. In
a study conducted in the Pima Indian population, the number
of swollen joints was predictive of death from CVD [37].
Similarly, the presence of severe extra-articular disease
clearly increased the risk for cardiovascular events in patients
with RA [2,38]. Duration of the disease has also been
associated with the presence of carotid plaques [39]. A
recent study conducted in 631 RA patients [40] showed that
the rate at which IMT increased was proportional to the
duration of disease. Another study [41], in 155 RA patients,
also demonstrated that patients with longstanding disease
have an increased Framingham risk score compared with
patients with early disease. (The Framingham risk score is
used to derive an estimated risk for developing coronary heart
disease within 10 years and is based on age, sex, total and
HDL cholesterol, blood pressure, diabetes and smoking.)
High Framingham scores were associated with coronary
artery calcification. The increased risk for CVD in RA patients
was also shown to be present 2 years before the fulfilment of
criteria for RA [7]. In addition, patients with very early
inflammatory polyarthritis are at increased risk for premature
death from CVD when their serum is positive for rheumatoid
factor [42]. These findings suggest that even preclinical
inflammation may contribute to increased risk for cardio-
vascular events.
Disease initiation and endothelial activation
In humans, atherosclerotic lesions occur in the large and
medium sized arteries and are characterized by an
asymmetrical focal thickening of the innermost layer of the
arterial wall, the intima. Atherosclerosis is a multifactorial
disease with strong epidemiological associations with a
variety of lifestyle-related and genetics-related risk factors (for
example, dyslipidaemia, smoking, diabetes mellitus and
hypertension). The common pathway, through which all of
these risk factors lead to atherosclerosis development, is
endothelial activation and subsequent endothelial dys-
function. The sequence of events that leads to early stages of
atherogenesis has been mostly characterized under condi-
tions of hypercholesterolaemia. Excess LDLs enter the intima
where they are retained by matrix proteoglycans. Here they
are subject to oxidative and enzymatic modifications, leading
to formation of pro-inflammatory phospholipids that may
induce endothelial cell activation [43].
Pro-inflammatory mediators such as tumour necrosis factor
(TNF)-α, are strongly linked to endothelial activation and
dysfunction [44]. Persistent endothelial activation leads to
endothelial dysfunction, characterized by reduced production
of nitric oxide and increased expression of adhesion
molecules and chemokines [1], resulting in impaired
vasorelaxation and recruitment of blood-borne mononuclear
cells such as monocytes and T lymphocytes. Endothelial
dysfunction has been detected in RA and SLE patients by
noninvasive tests such as the brachial flow-mediated dilata-
tion, as extensively reviewed elsewhere [45,46]. Endothelial
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individuals, but it could also indicate systemic inflammation
and prolonged exposure of endothelial cells to pro-inflam-
matory cytokines such as TNF-α (vide infra). Interestingly, in
animal models as well as in human clinical trials in RA and
SLE patients, high doses of statins can reduce inflammation
and improve endothelial function [47]. Statins are effective in
lowering LDL-cholesterol, but they also have immuno-
modulatory properties [48]. Both mechanisms of action might
be at play in reducing endothelial dysfunction.
Progression of atherosclerotic disease
Although atherosclerosis is initiated by the exposure to
traditional lifestyle risk factors, inflammation is a key driving
force at each stage of atherosclerosis development [43], with
both innate and adaptive cellular components of inflammation
involved in disease progression (Figure 2).
Myeloid cells, cytokines and atherosclerosis progression
Recruitment of blood-borne mononuclear cells is a key step in
atherogenesis. Even in hypercholesterolaemic murine models
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Table 1
Studies evaluating the risk of coronary heart disease in rheumatoid arthritis 
[Reference] 
(year) Study design RA definition n Estimated risk
[18] (2001) Prospective cohort ACR 1987 criteria 236 3.86-fold of combined CV events 
(MI + revascularization + stroke)
[4] (2003) Prospective cohort ACR 1987 criteria 525 2-fold risk for MI
1.48-fold risk for stroke
RA >10 years: 3-fold risk for MI
[84] (2003) Cross-sectional survey Rheumatologist diagnosis 9,093 2.15-fold risk for MI
[19] (2003) Prospective cohort Physician diagnosis 11,633 1.6-fold risk for MI
[5] (2005) Retrospective cohort  ACR 1987 criteria 603  2-fold risk for MI
6-fold risk for unrecognized MI
2-fold risk sudden death
[85] (2007) Retrospective cohort ACR 1987 criteria  239  0.1% to 0.3%/year MI
0.07%/year stroke
[2] (2008) Retrospective cohort Rheumatologist diagnosis 4,363  3.2% prevalence MI
1.9% prevalence stroke
ACR, American College of Rheumatology; CHD, coronary heart disease; CVD, cardiovascular disease; MI, myocardial infarction; RA, rheumatoid
arrthritis.
Table 2
Studies evaluating the risk of coronary heart disease in systemic lupus erythematosus
[Reference] 
(year) Study design SLE definition n Estimated risk
[11] (1997) Prospective cohort ACR criteria for SLE 498  5-fold risk for MI
50-fold risk in ages 35 to 44 years
[86] (1999) Retrospective cohort Rheumatologist diagnosis  8,742  2.27-fold risk for MI
3.8-fold risk for chronic heart failure 
[12] (2001) Retrospective cohort  Rheumatologist diagnosis 296  17.0-fold risk for CVD
10.1-fold risk for MI
7.9-fold risk for stroke
[87] (2004) Cross-sectional,  ACR criteria for SLE 202 (cross-sectional), 1.4-fold risk for CHD
prospective 47 (prospective) 0.6-fold risk for stroke
8.5% CHD events
10% stroke follow up
[88] (2004) Case control Physician diagnosis  770 1.46 risk for MI
ACR, American College of Rheumatology; CHD, coronary heart disease; CVD, cardiovascular disease; MI, myocardial infarction; SLE, systemic
lupus erythematosus.of atherosclerosis, genetic deletion or blockade of chemo-
kines (such as C-C chemokine ligands 2 and 5, and
fractalkine and its cognate receptors) and adhesion mole-
cules (such as vascular cell adhesion molecule-1) abrogates
monocyte recruitment and atherosclerosis in mice [43].
Blood-borne monocytes recruited through the endothelium
undergo differentiation into macrophages induced by
macrophage colony-stimulating factor. During this process
scavenger receptors are upregulated, mediating the uptake of
oxLDL, causing the formation of foam cells, which are the
hallmark of atherosclerotic lesions. Macrophages in athero-
sclerotic plaques exhibit features of activation and release a
host of pro-inflammatory mediators including TNF-α, which
leads to the engagement of the pro-inflammatory cytokine
cascade, resulting in IL-1 and IL-6 production. IL-6 in turn
stimulates production of large amounts of acute-phase
reactants, including C-reactive protein, serum amyloid A and
fibrinogen in the liver.
Cytokine upregulation is a general feature of inflammatory
diseases and could be a mechanism that links increased
atheroma formation in patients with RA and SLE. Several
cytokines with relevance to CVD could contribute to the
pathogenesis of atherosclerosis in RA and SLE.
TNF-α plays a dominant role in RA. TNF-α induces a pro-
inflammatory cascade, with upregulation of other mediators,
namely IL-1, IL-6 and IL-8, prostaglandins and matrix metallo-
proteinases (MMPs). Upregulation of adhesion molecules by
TNF-α on the vascular endothelium leads to cellular recruit-
ment of neutrophils and monocytes. It also stimulates the
proliferation of fibroblasts [49]. Introduction of the anti-TNF
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Figure 2
Formation and progression of atherosclerotic lesions. (a) Atherosclerosis disease initiation. Patients with rheumatoid arthritis and systemic lupus
erythematosus present with clustering of traditional risk factors, notably low high-density lipoprotein (HDL) levels and pro-atherogenic lipid
particles, leading to premature establishment of atherosclerotic lesions compared with age-matched and sex-matched control individuals. (b)
Progression. Inflammatory disease activity and duration is emerging as a key determinant of the clinical association between cardiovascular disease
(CVD) and inflammatory disease. Pro-inflammatory mediators and immune dysregulation features may enhance susceptibility to risk factors and
establish chronic inflammation in vascular lesions. (c) Complications. Both inflammatory features and prothrombotic pathways may enhance the
likelihood of acute events, increasing mortality. IFN, interferon; LDL, low-density lipoprotein; Lp(a), lipoprotein(a); MCP, monocyte chemoattractant
protein; MIF, macrophage migration inhibitory factor; MMP, matrix metalloproteinase; oxLDL, oxidized low-density lipoprotein; PG, prostaglandin;
VCAM, vascular cell adhesion molecule; TF, tissue factor; TNF, tumour necrosis factor.treatments has dramatically improved the outcome of severe
RA [50]. Blockade of TNF-α in RA reduces circulating
cytokine levels, leucocyte trafficking and platelet levels, all
factors that may promote thrombotic and atherosclerotic
complications [50]. In studies of hypercholesterolaemic apo-
lipoprotein (apo)E-/- mice, genetic deletion of TNF-α or
treatment with recombinant soluble TNF receptor I led to a
reduction in atherosclerotic lesions [51]. Experimental studies
using apoE-/- TNF-/- mice also demonstrated a significantly
smaller lesion size in the aortic sinus compared with that of
apoE-/- mice [51]. Although the failure of TNF blockers in
heart failure has thus far discouraged further trials in other
CVD, evidence to support the hypothesis that TNF blockers
are protective against CVD has started to accumulate in RA
cohorts. In a Swedish registry cohort [52], treatment with
TNF inhibitors was associated with a lower incidence of first
MI in patients with RA. Anti-TNF treatment in RA patients
increases HDL-cholesterol levels [53], insulin sensitivity [54]
and reduces carotid IMT [55] and MI [56].
Recently, macrophage migration inhibitory factor (MIF) has
emerged as a potential link between RA, SLE and athero-
sclerosis development (for review, see [57]). Originally,
described as ‘a soluble factor released from T cells in delayed
hypersensitivity responses inhibiting migration of macro-
phages’, MIF is considered a pleiotropic cytokine with roles in
several inflammatory diseases. MIF induces the pro-inflam-
matory mediators TNF-α, IL-1, IL-6 and MMPs. It can activate
T cells, promote angiogenesis and induce proliferation of
cells, while inhibiting p53 expression and apoptosis of the
same cells [57,58]. MIF can be induced by oxLDL, which is
an initiating factor in atherogenesis, and so expression of MIF
early on may enhance pro-inflammatory responses and lesion
progression [58]. MIF immunoneutralization or genetic
deletion reduces disease activity in animal models of arthritis
and lupus. In mice with advanced atherosclerosis, MIF
blockade led to plaque regression and reduced monocyte
and T-cell content in the plaques. Interestingly, gluco-
corticoids can induce the expression of MIF in multiple cell
types [57], which is a function of potential relevance to the
development of CVD in those patients receiving chronic
treatment. Increased serum levels of MIF have been detected
in SLE patients compared with healthy control individuals
[57], and correlations were reported between MIF serum
levels and SLE-related damage scores and glucocorticoid
exposure.
The type I interferon cytokines (interferon [IFN]-α and IFN-β)
play a causative role in SLE. Type I IFN-α is produced by
dendritic cells in response to viral or bacterial infections,
sensed through Toll-like receptor (TLR)-9. Auto-antigens
such as self-DNA, exposed by apoptotic cells, may also
trigger TLR-9 signalling, resulting in IFN-α production [59].
IFNs play many roles including inhibition of cell proliferation,
interfering with viral infections, proliferation of memory T cells
and increased antigen presentation activity by dendritic cells
[60]. Type I IFNs were recently linked to impairment of
vascular repair by circulating endothelial progenitor cells. SLE
patients have decreased numbers of endothelial progenitor
cells, with increased endothelial cell apoptosis, and
decreased pro-angiogenic and repair capacity [59]. IFN-α
has anti-proliferative effects on endothelial progenitor cells in
vitro. SLE patients have elevated levels of IFN-α, which corre-
lates with disease severity [60] and impaired endothelial
function [61]. Interestingly, IFN-α produced by plasmacytoid
dendritic cells has been detected in human carotid plaques,
where it could sensitize antigen-presenting cells to the TLR-4
ligand lipopolysaccharide, thereby promoting the production
of pro-inflammatory molecules [62]. By contributing to endo-
thelial dysfunction/damage and inducing pro-inflammatory
responses within the atherosclerotic plaque, IFN-α could
promote atherosclerosis in patients with inflammatory
diseases.
Lymphocytes and immune dysregulation
T cells infiltrate atherosclerotic lesions, even in early stages of
disease. Such infiltrates are predominantly CD45RO-expres-
sing memory CD4+ T cells, most of which bear the T-cell
receptor αβ. They appear to be in close contact with major
histocompatibility complex (MHC) class II expressing
macrophages and dendritic cells. Both human and animal
studies have thus far shown a predominantly T-helper (Th)1
pattern in atherosclerosis, with immunopositivity for the
classic Th1 cytokine IFN-γ and Th1-stimulating cytokines IL-
12 and IL-18. In apoE-/- mice lacking IFN-γ or its receptor, the
development of atherosclerosis is inhibited [43].
During the past decade, an unusual subpopulation of CD4+
T cells lacking the co-stimulatory receptor CD28 have been
suggested to link atherosclerotic syndromes with RA. Such
CD4+ T cells exhibit a spectrum of regulatory receptors that
are usually only seen on natural killer cells. Such regulatory
receptors include perforin, members of the killer immuno-
globulin-like receptor family, and the receptor for the
chemokine fractalkine. In RA, circulating CD4+CD28null cells
are increased and correlate with preclinical atherosclerotic
disease and endothelial dysfunction. Such cells are also
increased in the circulation and in plaques of patients with
acute coronary syndrome (ACS) [63] and possess endo-
thelial cell cytotoxic activity [64].
An additional mechanism that could also explain the
increased incidence of CVD in patients with inflammatory
diseases is the failure of regulatory feedback mechanisms,
such as production of anti-inflammatory cytokines IL-10 and
transforming growth factor (TGF)-β by regulatory T cells.
T-cell-specific genetic deficiency in the TGF-β receptor leads
to plaque destabilization, whereas regulatory T cells have the
ability to reduce atherosclerotic burden in hyperlipidaemic
mice [43]. In RA CD4+CD25+ regulatory T cells have a
defect in their suppressive functions, which was restored
during treatment with TNF blockers [65].
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evoked to explain increased inflammation in lupus-like models
of disease. The gld and lpr mouse strains have inactivating
mutations in Fas ligand and Fas, respectively, and they suffer
from lupus-like disease. (Fas ligand and Fas are trans-
membrane proteins on the cell surface; binding of Fas ligand
to its receptor Fas induces apoptosis.) Although these mice
typically do not exhibit signs of atherosclerosis, they are
susceptible to atherosclerotic lesion formation when they are
fed an atherogenic diet [66]. ApoE-/- mice crossed with gld
mice developed lesions containing a twofold to threefold
increase in macrophages and CD3+ lymphocytes as
compared with apoE-/- mice [67]. A similar increase in
lymphocytes and macrophage accumulation within the
lesions were observed after bone marrow transfer from lupus-
prone strains developed on a C57BL/6 background to LDL
receptor-deficient mice [68,69], even in the presence of
lower levels of cholesterol and triglycerides. Furthermore, an
increase in the expression of the MHC class II molecule I-Ab
in mice with lupus-like disease compared with control animals
was observed, and there were significantly higher antibody
titres to oxLDL and cardiolipin [67-69].
Thrombotic complications
ACS such as MI occur when thrombosis ensues on an
atherosclerotic plaque, suddenly limiting blood flow through
the coronary artery. Acute thrombosis is often triggered by
sudden plaque rupture or erosion [43], but heterogeneity of
pathological substrates for thrombosis has been documented
[70]. MI is often caused by plaques that only moderately
restrict the vessel lumen (by <50% of the lumen diameter) [71].
Plaque vulnerability
The chance of plaque rupture is determined by the strength
and thickness of the fibrous cap, surrounding the inflam-
matory and necrotic ‘core’ of the plaque. The cap, made up of
smooth muscle cells (SMCs) either recruited from the media
or derived from progenitors, forms a protective barrier
encasing the core, preventing the prothrombotic material -
tissue factor and phospholipids - from contacting the arterial
blood flow [43]. ‘High-risk’ atherosclerotic plaques are
characterized by their composition rather than by their impact
on the vessel lumen. A high-risk plaque is characterized by a
large lipidic/necrotic core with increased number of activated
monocytes and lymphocytes. The fibrous cap is also thinner
due to SMC apoptosis and proteolytic degradation of the
fibrous proteins. On the contrary, a ‘stable’ plaque is charac-
terized by its thick fibrous cap, containing increased amounts
of fibrous proteins and SMCs, and generally a smaller pro-
inflammatory/prothrombotic core; such plaques are less
prone to rupture.
There is evidence that plaques obtained from patients who
have experienced an ACS have a higher content of macro-
phages and activated T lymphocytes at sites of coronary
thrombosis [72]. Also, they are often found in clusters within
the fibrous cap, in particular in the ‘shoulder’ area of the
lesion, the border between normal vessel and atherosclerotic
plaque, where plaque rupture is thought to occur most often.
A retrospective autopsy study comparing 41 patients with RA
with sex-, age- and autopsy date-matched control individuals
did not identify significant differences between groups in
severity of the coronary stenoses in cross-sectional area or
the number of vessels affected. However, RA patients with
clinical history of CVD were more likely to have coronary
lesions with a ‘high-risk’ rather than a ‘stable’ plaque
phenotype [73]. This finding is in agreement with a long
‘silent’ history of coronary artery disease, with increased
incidence of MI and sudden death [5,6].
Plaque stability can be influenced by cytokines via a variety of
mechanisms. First, cytokines can affect the amount of fibrous
proteins produced by SMCs. IFN-γ inhibits collagen
production, whereas TGF-β has the opposite effect. Second,
cytokines such as TNF-α and IL-1 can induce expression of
MMPs in SMCs and macrophages, which degrade the
fibrous cap. MIF can induce MMP expression and may also
contribute to plaque instability by increasing monocyte
recruitment and retention in the plaque. Third, apoptosis of
SMCs can be induced by IFN-γ and TNF-α. Finally, cytokines,
in particular TNF-α, can induce expression of tissue factor,
which is the major initiator of the thrombotic cascade and
whose increased expression is a feature of plaques in
patients with ACS. Therefore, pro-inflammatory cytokines can
have both a localized effect on the plaque architecture and
determine occurrence of thrombotic events, and a more
systemic effect, in which they affect cholesterol levels, insulin
resistance and endothelial function.
Genetic associations
Recently, single nucleotide polymorphisms (SNPs) with an
impact on immune responses have emerged as shared
genetic risk factors in RA and MI. The expression of MHC
class II is regulated by the transactivator MHC2TA. A SNP,
namely the A168G polymorphism in the type III promoter of
MHC2TA, was recently associated with RA, multiple
sclerosis and MI. This polymorphism was associated with
lower expression of MHC2TA after stimulation of peripheral
blood cells with IFN-γ, leading the authors to speculate that
less efficient antigen presentation in response to
inflammatory stimuli to regulatory T cells may promote
disease [74]. Interestingly, statins have been shown to
downregulate MHC2TA expression by inhibition of the
inducible IV promoter of MHC2TA [48]. However, no
evidence of association of this MHC2TA variant with RA
could subsequently be detected in independent cohorts
[75,76], and studies in larger sample sizes are awaited to
clarify the role of this SNP in the aetiology of RA [75].
Interestingly, polymorphisms in the region of the TNFAIP3
gene were recently linked to RA and SLE [77,78]. TNFAIP3
encodes the de-ubiquitinating enzyme A20, an endogenous
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a transcription factor that is activated by TNF or IL-1/TLR
signalling pathways, which induces transcription of pro-
inflammatory genes. In atherosclerosis, NF-κB is activated at
sites of the arterial wall that are prone to lesion development.
In animal studies, ApoE-/-A20-/- mice had increased
atherosclerosis, whereas mice with A20 over-expression had
decreased atherosclerosis [79]. SNPs in the TNFAIP3 gene
region may cause reduced expression or reduced activity of
A20 [77], therefore contributing to an uncontrolled
inflammatory response and autoimmunity and potentially
accelerated atherosclerosis in these patients.
Antiphospholipid antibodies
Antiphospholipid antibodies are the hallmark of the antiphos-
pholipid syndrome, which is characterized by recurrent
thrombosis and is associated with SLE. Between 30% and
50% of patients with SLE have antiphospholipid antibodies,
and approximately one-third develop antiphospholipid syn-
drome [23]. Many of these antibodies, such as anticardiolipin
(aCL), recognize phospholipid-binding plasma proteins such
as  β2-glycoprotein I (GPI), which is anticoagulant. Never-
theless, there is some new evidence to suggest that they may
also play a role in the development of atherosclerotic disease.
Antibodies to β2-GPI may lead to endothelial activation
and/or damage, as well as enhance oxLDL uptake by
macrophages, contributing to recruitment of immune cells to
the vascular wall. Furthermore, immunization with β2-GPI
leads to vascular lesions in LDL receptor-/- mice, suggesting
that immune recognition might also play a role [80].
However, in SLE cohorts no correlation was found between
aCL antibodies and indices of atherosclerosis extent and
severity such as carotid IMT [81,82]. However, association
was found with thrombotic complications such as MI. This
paradox can potentially be explained by the ability of aCL to
cause thrombosis even in the absence of underlying
advanced atherosclerotic plaque [81]. Some patients with
RA may have elevated levels of aCL [83]. In contrast with
SLE patients, however, RA patients exhibited an increased
carotid IMT compared with RA patients without elevated
auto-antibodies [13]. However, in one study, only 17 out of
83 patients were found to have increased antibodies to aCL,
and larger cohorts are needed to address this observation.
Conclusions
An increased prevalence of pro-atherogenic risk factors in
patients with RA and SLE compared with age-matched
control individuals may very well contribute to the initiating
stages of disease. However, the dysregulated inflammation
that characterizes inflammatory diseases may increase
susceptibility to traditional risk factors and the likelihood that
a chronic inflammatory response will ensue at the arterial
sites. Potentially, shared pathogenic pathways are also at
play. The dissection of the molecular mechanisms underlying
atherosclerosis and classic inflammatory diseases will no
doubt help us to understand how inflammation causes CVD
in both the general population and in the subgroups of
patients with inflammatory diseases.
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